Collaborative Licensing Hyloris has active and recent partnering activity, including exclusive worldwide development and commercialization licensing with RedHill Biopharma for RHB-102, signaling a readiness to collaborate with larger partners to accelerate market access and expand the pipeline.

Expansion Through Reformulation With a broad portfolio of 28 products focused on reformulation, repurposing, and NCEs, Hyloris aims to shorten development timelines using established regulatory pathways, creating multiple near-term sellable assets that can be positioned with payors and clinicians seeking proven safety profiles.

High-Barrier Generics The company already has high-barrier generic products approved in the U.S. and is developing another, offering a pathway to early revenue generation and patent protection advantages that can attract contract manufacturing and distribution partners.

Strategic Regional Footprint Based in Belgium with Euronext listing and a portfolio targeting global markets, Hyloris presents partnering opportunities across EU and North American channels, leveraging regional incentives and healthcare economics favorable to reformulated therapies.

Pipeline Diversification With a pipeline expanding to over 30 products and ongoing early-stage development across multiple indications, there are multiple entry points for partnerships in specialty areas such as atrial fibrillation care, postoperative pain, oral care for anticoagulant patients, and other unmet needs that can align with distributor and co-development strategies.